Can C-peptide mediated anti-inflammatory effects retard the development of microvascular complications of type 1 diabetes?

Diabetes/Metabolism Research and Reviews

Volumn 29, Issue 5, 2013, Pages 357-362

  Luppi, Patrizia ^a   Kallas, Åsa ^b   Wahren, John ^b  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

C peptide; Inflammation; Type 1 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ANTIINFLAMMATORY AGENT; C PEPTIDE; C REACTIVE PROTEIN; CELL ADHESION MOLECULE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PADGEM PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIG INSULIN; PROINSULIN; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; REACTIVE OXYGEN METABOLITE; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; BIOLOGICAL ACTIVITY; BLOOD VESSEL INJURY; CELL FUNCTION; CELL PROLIFERATION; CELL SURFACE; CLINICAL OBSERVATION; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DISEASE DURATION; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SYNTHESIS; MICROALBUMINURIA; MICROCIRCULATION; MONOCYTE; NERVE CONDUCTION; NERVE FUNCTION; NEUROBLASTOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET TRANSPLANTATION; PERIPHERAL NERVE; PRIORITY JOURNAL; REVIEW; SCIATIC NERVE; SMOOTH MUSCLE FIBER; STREPTOZOCIN DIABETES; SYSTEMIC CIRCULATION; URINE LEVEL; VASCULAR ENDOTHELIUM; VIBRATION SENSE;

C-PEPTIDE; INFLAMMATION; TYPE 1 DIABETES;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DIABETIC ANGIOPATHIES; ENDOTHELIUM, VASCULAR; HUMANS; MICROVESSELS;

EID: 84879676932     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2409     Document Type: Review

References (65)

1. Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004; 88(4): 947-999.
2. Groop PH, Thomas MC, Moran JL, et al. The presence and severity of chronic kidney disease predicts all-cause mortality in type 1 diabetes. Diabetes 2009; 58(7): 1651-1658.
3. Zhang W, Liu H, Al-Shabrawey M, Caldwell RW, Caldwell RB. Inflammation and diabetic retinal microvascular complications. J Cardiovasc Dis Res 2011; 2(2): 96-103.
4. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010; 107(9): 1058-1070.
5. Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest 2001; 108(9): 1341-1348.
6. Fulton D, Gratton JP, McCabe TJ, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399(6736): 597-601.
7. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399(6736): 601-605.
8. De Caterina R, Libby P, Peng HB, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995; 96(1): 60-68.
9. Moncada S, Palmer RM, Higgs EA. The discovery of nitric oxide as the endogenous nitrovasodilator. Hypertension 1988; 12(4): 365-372.
10. He Z, Rask-Madsen C, King GL. Pathogenesis of diabetic microvascular complications. In International textbook of diabetes mellitus (3rd edn) DeFronzo RA, Ferrannini E, Keen H, Zimmet P, eds. John Wiley & Sons Ltd: London, 2004; 1135-1159.
11. Devaraj S, Dasu MR, Jialal I. Diabetes is a proinflammatory state: a translational perspective. Expert Rev Endocrinol Metab 2010; 5(1): 19-28.
12. Schram MT, Chaturvedi N, Schalkwijk CG, Fuller JH, Stehouwer CD. Markers of inflammation are cross-sectionally associated with microvascular complications and cardiovascular disease in type 1 diabetes - the EURODIAB Prospective Complications Study. Diabetologia 2005; 48(2): 370-378.
13. Soedamah-Muthu SS, Chaturvedi N, Schalkwijk CG, Stehouwer CD, Ebeling P, Fuller JH. Soluble vascular cell adhesion molecule-1 and soluble E-selectin are associated with micro- and macrovascular complications in type 1 diabetic patients. J Diabetes Complications 2006; 20(3): 188-195.
14. Plesner A, Greenbaum CJ, Gaur LK, Ernst RK, Lernmark A. Macrophages from high-risk HLA-DQB1*0201/*0302 type 1 diabetes mellitus patients are hypersensitive to lipopolysaccharide stimulation. Scand J Immunol 2002; 56(5): 522-529.
15. Matteucci E, Giampietro O. Oxidative stress in families of type 1 diabetic patients: further evidence. Diabetes Care 2001; 24(1): 167-168.
16. Cifarelli V, Libman IM, Deluca A, Becker D, Trucco M, Luppi P. Increased expression of monocyte CD11b (Mac-1) in overweight recent-onset type 1 diabetic children. Rev Diabet Stud 2007; 4(2): 112-117.
17. Rosa JS, Flores RL, Oliver SR, Pontello AM, Zaldivar FP, Galassetti PR. Sustained IL-1alpha, IL-4, and IL-6 elevations following correction of hyperglycemia in children with type 1 diabetes mellitus. Pediatr Diabetes 2008; 9(1): 9-16.
18. Beyan H, Drexhage RC, van der Heul NL, et al. Monocyte gene-expression profiles associated with childhood-onset type 1 diabetes and disease risk: a study of identical twins. Diabetes 2010; 59(7): 1751-1755.
19. Delmastro MM, Piganelli JD. Oxidative stress and redox modulation potential in type 1 diabetes. Clin Dev Immunol 2011; 2011: 593863.
20. Schalkwijk CG, Poland DC, van Dijk W, et al. Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42(3): 351-357.
21. Lampeter ER, Kishimoto TK, Rothlein R, et al. Elevated levels of circulating adhesion molecules in IDDM patients and in subjects at risk for IDDM. Diabetes 1992; 41(12): 1668-1671.
22. Elhadd TA, Kennedy G, Hill A, et al. Abnormal markers of endothelial cell activation and oxidative stress in children, adolescents and young adults with type 1 diabetes with no clinical vascular disease. Diabetes Metab Res Rev 1999; 15(6): 405-411.
23. Järvisalo MJ, Raitakari M, Toikka JO, et al. Endothelial dysfunction and increased arterial intima-media thickness in children with type 1 diabetes. Circulation 2004; 109(14): 1750-1755.
24. Astrup AS, Tarnow L, Pietraszek L, et al. Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10years: association with mortality and decline of glomerular filtration rate. Diabetes Care 2008; 31(6): 1170-1176.
25. Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 2008; 19(3): 433-442.
26. Steiner DF, Cunningham D, Spigelman L, Aten B. Insulin biosynthesis: evidence for a precursor. Science 1967; 157(789): 697-700.
27. Wahren J, Kallas A, Sima AA. The clinical potential of C-peptide replacement in type 1 diabetes. Diabetes 2012; 61(4): 761-772.
28. Cifarelli V, Geng X, Styche A, Lakomy M, Trucco M, Luppi P. C-peptide reduces high glucose-induced apoptosis of endothelial cells and decreases NAD(P)H-oxidase reactive oxygen species generation. Diabetologia 2011; 54: 2702-2712.
29. Chima RS, Maltese G, Lamontagne T, et al. C-peptide ameliorates kidney injury following hemorrhagic shock. Shock 2011; 35(5): 524-529.
30. Luppi P, Cifarelli V, Wahren J. C-peptide and long-term complications of diabetes. Pediatr Diabetes 2011; 12(3): 276-292.
31. Bhatt MP, Lim YC, Hwang J, Na S, Kim YM, Ha KS. C-Peptide prevents hyperglycemia-induced endothelial apoptosis through inhibition of reactive oxygen species-mediated transglutaminase 2 activation. Diabetes 2013; 62(1): 243-253.
32. Vejandla H, Hollander JM, Kothur A, Brock RW. C-Peptide reduces mitochondrial superoxide generation by restoring complex I activity in high glucose-exposed renal microvascular endothelial cells. ISRN Endocrinol 2012; 2012: 162802.
33. Li ZG, Zhang W, Sima AA. C-peptide enhances insulin-mediated cell growth and protection against high glucose-induced apoptosis in SH-SY5Y cells. Diabetes Metab Res Rev 2003; 19(5): 375-385.
34. Sima AA, Li ZG. The effect of C-peptide on cognitive dysfunction and hippocampal apoptosis in type 1 diabetic rats. Diabetes 2005; 54(5): 1497-1505.
35. Bugliani M, Torri S, Lupi R, et al. Effects of C-peptide on isolated human pancreatic islet cells. Diabetes Metab Res Rev 2007; 23(3): 215-219.
36. Al-Rasheed NM, Willars GB, Brunskill NJ. C-peptide signals via Galpha i to protect against TNF-alpha-mediated apoptosis of opossum kidney proximal tubular cells. J Am Soc Nephrol 2006; 17(4): 986-995.
37. Chima RS, LaMontagne T, Piraino G, Hake PW, Denenberg A, Zingarelli B. C-peptide, a novel inhibitor of lung inflammation following hemorrhagic shock. Am J Physiol Lung Cell Mol Physiol 2011; 300(5): L730-739.
38. Scalia R, Coyle KM, Levine BJ, Booth G, Lefer AM. C-peptide inhibits leukocyte-endothelium interaction in the microcirculation during acute endothelial dysfunction. FASEB J 2000; 14(14): 2357-2364.
39. Kobayashi Y, Naruse K, Hamada Y, et al. Human proinsulin C-peptide prevents proliferation of rat aortic smooth muscle cells cultured in high-glucose conditions. Diabetologia 2005; 48(11): 2396-2401.
40. Mughal RS, Scragg JL, Lister P, et al. Cellular mechanisms by which proinsulin C-peptide prevents insulin-induced neointima formation in human saphenous vein. Diabetologia 2010; 53(8): 1761-1771.
41. Cifarelli V, Luppi P, Tse HM, He J, Piganelli J, Trucco M. Human proinsulin C-peptide reduces high glucose-induced proliferation and NF-kappa B activation in vascular smooth muscle cells. Atherosclerosis 2008; 201(2): 248-257.
42. Walcher D, Babiak C, Poletek P, et al. C-Peptide induces vascular smooth muscle cell proliferation: involvement of SRC-kinase, phosphatidylinositol 3-kinase, and extracellular signal-regulated kinase 1/2. Circ Res 2006; 99(11): 1181-1187.
43. Haidet J, Cifarelli V, Trucco M, Luppi P. C-peptide reduces pro-inflammatory cytokine secretion in LPS-stimulated U937 monocytes in condition of hyperglycemia. Inflamm Res 2012; 61(1): 27-35.
44. Kitamura T, Kimura K, Makondo K, et al. Proinsulin C-peptide increases nitric oxide production by enhancing mitogen-activated protein-kinase-dependent transcription of endothelial nitric oxide synthase in aortic endothelial cells of Wistar rats. Diabetologia 2003; 46(12): 1698-1705.
45. Forst T, De La Tour DD, Kunt T, et al. Effects of proinsulin C-peptide on nitric oxide, microvascular blood flow and erythrocyte Na+, K+-ATPase activity in diabetes mellitus type I. Clin Sci (Lond) 2000; 98(3): 283-290.
46. Galuska D, Pirkmajer S, Barres R, Ekberg K, Wahren J, Chibalin AV. C-peptide increases Na, K-ATPase expression via PKC- and MAP kinase-dependent activation of transcription factor ZEB in human renal tubular cells. PLoS One 2011; 6(12): e28294.
47. Samnegård B, Jacobson SH, Jaremko G, Johansson BL, Sjöquist M. Effects of C-peptide on glomerular and renal size and renal function in diabetic rats. Kidney Int 2001; 60(4): 1258-1265.
48. Nordquist L, Lai EY, Sjöquist M, Patzak A, Persson AE. Proinsulin C-peptide constricts glomerular afferent arterioles in diabetic mice. A potential renoprotective mechanism. Am J Physiol Regul Integr Comp Physiol 2008; 294(3): R836-841.
49. Kamikawa A, Ishii T, Shimada K, et al. Proinsulin C-peptide abrogates type-1 diabetes-induced increase of renal endothelial nitric oxide synthase in rats. Diabetes Metab Res Rev 2008; 24(4): 331-338.
50. Nordquist L, Shimada K, Ishii T, Furuya DT, Kamikawa A, Kimura K. Proinsulin C-peptide prevents type-1 diabetes-induced decrease of renal Na+-K+-ATPase alpha1-subunit in rats. Diabetes Metab Res Rev 2010; 26(3): 193-199.
51. Nordquist L, Brown R, Fasching A, Persson P, Palm F. Proinsulin C-peptide reduces diabetes-induced glomerular hyperfiltration via efferent arteriole dilation and inhibition of tubular sodium reabsorption. Am J Physiol Renal Physiol 2009; 297(5): F1265-1272.
52. Cotter MA, Ekberg K, Wahren J, Cameron NE. Effects of proinsulin C-peptide in experimental diabetic neuropathy: vascular actions and modulation by nitric oxide synthase inhibition. Diabetes 2003; 52(7): 1812-1817.
53. Stevens MJ, Zhang W, Li F, Sima AA. C-peptide corrects endoneurial blood flow but not oxidative stress in type 1 BB/Wor rats. Am J Physiol Endocrinol Metab 2004; 287(3): E497-505.
54. Panero F, Novelli G, Zucco C, et al. Fasting plasma C-peptide and micro- and macrovascular complications in a large clinic-based cohort of type 1 diabetic patients. Diabetes Care 2009; 32(2): 301-305.
55. Fioretto P, Steffes MW, Sutherland DE, Goetz FC, Mauer M. Reversal of lesions of diabetic nephropathy after pancreas transplantation. N Engl J Med 1998; 339(2): 69-75.
56. Johansson BL, Borg K, Fernqvist-Forbes E, Kernell A, Odergren T, Wahren J. Beneficial effects of C-peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitus. Diabet Med 2000; 17(3): 181-189.
57. Ekberg K, Brismar T, Johansson BL, Jonsson B, Lindstrom P, Wahren J. Amelioration of sensory nerve dysfunction by C-peptide in patients with type 1 diabetes. Diabetes 2003; 52(2): 536-541.
58. Ekberg K, Brismar T, Johansson BL, et al. C-peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy. Diabetes Care 2007; 30(1): 71-76.
59. Leahy JL, Hirsch IB, Peterson KA, Schneider D. Targeting beta-cell function early in the course of therapy for type 2 diabetes mellitus. J Clin Endocrinol Metab 2010; 95(9): 4206-4216.
60. Kim BY, Jung CH, Mok JO, Kang SK, Kim CH. Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients. Acta Diabetol 2012; 49(1): 9-15.
61. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002; 16(3): 438-440.
62. Moriwaki Y, Inokuchi T, Yamamoto A, et al. Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol 2007; 44(4): 215-218.
63. Reynolds K, Goldberg RB. Thiazolidinediones: beyond glycemic control. Treat Endocrinol 2006; 5(1): 25-36.
64. Staels B, Maes M, Zambon A. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease. Nat Clin Pract Cardiovasc Med 2008; 5(9): 542-553.
65. Foyt H, Daniels M, Milad M, Wahren J. Pharmacokinetics, safety, and tolerability of a long-acting C-peptide (CBX129801) in patients with type 1 diabetes. Diabetologia 2012; 55(Suppl 1): S455.